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Fanconi anemia (FA) is a rare autosomal recessive disorder characterized by physical abnormali-ties, bone marrow failure, and an increased risk 
of malignancy. Hematologic abnormalities occur in vir-
tually all patients with FA at a median age of 7 years 
(range, birth to 41 years).1,2 Based on clinical data in the 
International Fanconi Anemia Registry, the cumula-
tive incidence of bone marrow failure by age 40 years is 
90%. Initial hematologic findings are most commonly 
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BACKGROUND AND OBJECTIVE: hematopoietic cell transplantation (hCt) is the only therapeutic modality 
capable of correcting the hematologic manifestations of fanconi anemia (fa). the development of well-tolerated 
immunosuppressive conditioning regimens for fa patients undergoing hCt has proven to be a challenging task 
for hematologists.
DESIGN AND SETTINGS: retrospective, patients referred to the hematology, oncology and stem cell transplan-
tation research center.
PATIENTS AND METHODS: We analyzed the outcome of 53 fa patients who had undergone hCt between 
1992 and 2010. the median age at transplantation was 9 years. Patients received transplants from an hLa-identi-
cal sibling (n=39) or matched relative (n=9) and one-antigen locus mismatched other relative/sibling (n=5). all 
of the patients underwent transplantation with fludarabine and non-fludarabine-based conditioning regimens. 
no radiation therapy was given.
RESULTS: the median follow-up period for survivors was 13.5 months (range, 3 months-13.5 years). the 3-year 
overall survival (os) was 60.6%. the 3-year os for patients who did or did not receive fludarabine-based pre-
parative regimens for the allograft was 36.4%, and 70%, respectively. however, there were no statistically sig-
nificant differences in os rates between these two groups (P=.112). Graft failure occurred in 4 patients (7.5%). 
all of these 4 patients had received fludarabine-based conditioning regimens. the incidence of acute GVhD 
after fludarabine-based regimens was 45% versus 79% in non-fludarabine-based regimens (P=.03).
CONCLUSION: Despite the high incidence of acute GVhD (78.6%) in the non-fludarabine group, which re-
sulted in the death of some patients, the os rate was significantly better than in fludarabine recipients. therefore, 
in spite of the fact that recent studies advocate the fludarabine-based conditioning regimens, we propose to 
conduct a multicenter, prospective study to evaluate the outcomes of regimens employed in fa patients. 
pancytopenia; however, some patients present with my-
elodysplastic syndrome (MDS) or acute myeloid leu-
kemia (AML). Treatment for hematological disease in 
FA patients can either be supportive with blood prod-
uct transfusions, anabolic steroids and hematopoietic 
growth factors, or curative with hemopoietic cell trans-
plantation (HCT).3
The basic understanding and diagnosis of FA pa-
tients has been greatly advanced over the past decade 
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with subtyping of FA cell lines into discrete comple-
mentation groups, each representing mutation in spe-
cific genes.4 To date, mutations in 14 complementation 
groups (A, B, C, D1, D2, E, F, G, I, J, L, M, N and O) 
have been classified in FA.5 Allogeneic HCT is current-
ly the only treatment that can restore normal hemato-
poiesis, as well as prevent/treat myeloid malignancies, 
although it does not prevent the occurrence of solid tu-
mors, mostly head and neck small cell carcinoma.6,7 
In this retrospective study, we report the long-term 
outcomes of transplantation using fludarabine and non-
fludarabine-based conditioning regimens in patients 
with FA who have undergone HCT since 1992. No 
radiation therapy was given to patients who received 
conditioning regimens. 
PATIENTS AND METHODS
Between January 1992 and July 2010, all patients with 
confirmed FA who were referred to our center and had 
family-related donors, underwent transplants. The 
number of infused red blood cells, platelets and the 
use of corticosteroids were registered. The diagnosis of 
FA was made in all patients by documenting increased 
chromosomal breakage with diepoxybutane and/or mi-
tomycin C. Bone marrow status was determined within 
4 weeks before HCT by histopathologic analysis of 
bone marrow aspiration and biopsy.
All donors were tested before transplant and had no 
evidence of FA. In all donor-recipient pairs, histocom-
patibility was determined by serology or low resolution 
molecular typing for human leukocyte antigen (HLA)-
A and -B and by allelic typing for -DRB1. Since 2007, 
the search for finding a related donor in the extended 
family has been performed in all patients whose parents 
are relatives and in whom an HLA-matched sibling do-
nor was not available. In patients with other related full-
matched donors, high resolution typing for class I and II 
alleles was completed for recipient/donor pairs. A par-
tially matched related donor was considered as the last 
option for patients without an HLA-matched donor. 
Bone marrow (BM) or peripheral blood (PB) was 
used as the source of stem cells. BM was collected by the 
standard techniques from the donor on the day of infu-
sion. In the PB group, donors received 10 µg/kg/day of 
granulocyte colony-stimulating factor (G-CSF) for five 
consecutive days before the stem cell collection. Of the 
53 patients included in this study, 39 patients (73.6%) 
received stem cells from healthy full HLA-matched sib-
lings, 7 patients from their parents (HLA-matched), 
and 2 patients from their aunt (HLA-matched). Four 
patients were transplanted from their one-antigen mis-
matched parents and one patient underwent one-anti-
gen mismatched sibling transplantation.
The patients were divided into two groups ac-
cording to the conditioning regimens. The first group 
(non-fludarabine based) received oral busulfan (0.2 
mg/kg/day for four consecutive days in divided doses) 
plus cyclophosphamide (15 mg/kg/day intravenously 
for 4 days) with the addition of horse antithymocyte 
globulin (ATG) (10 mg/kg intravenously) for those pa-
tients who received blood or platelet products and/or 
underwent HCT from other relatives or an HLA-mis-
matched donor. The second group (fludarabine-based) 
received fludarabine (30 mg/m2/day intravenously for 
five consecutive days) plus horse ATG (10 mg/kg/day 
intravenously for four consecutive days) and cyclophos-
phamide (10 mg/kg/day intravenously for two con-
secutive days) conditioning regimen. Treatment related 
adverse events experienced by the patients were graded 
using the National Cancer Institute (NCI) Common 
Toxicity Criteria (NCI, 1998). Cyclosporine A (CsA) 
(1.5 mg/kg IV from -2 to +6 and 3 mg/kg IV from +7in 
PBSC and +11 in BMSC) with or without methotrex-
ate (10mg/m2 on +2day and 5 mg/m2 on+3,+6days) 
was used as a graft-versus-host disease (GVHD) pro-
phylaxis regimen. Ciclosporine levels were monitored 
twice, weekly.
The median number of infused MNC and CD34 in 
PBSC was 8.18×108/kg and 2.8×106/kg, and the me-
dian number of infused MNC and CD34 in BMSC was 
3.5×108/kg and 3.4×106/kg, respectively. The median 
time to granulocyte engraftment and platelet recovery 
was 14 (range: 9-55) and 20 days (range: 9-86), respec-
tively. Patients were hospitalized in single rooms with 
highly efficient particulate air filters. Aciclovir was given 
as prophylaxis for herpes simplex and varicella-zoster 
virus. It was started at 15 mg/kg/day intravenously in 
divided doses from day -9. Trimethoprim (TMP)-sul-
famethoxazole was given as Pneumocystis jiroveci pro-
phylaxis. It was started at 10 mg/kg/TMP/day orally 
in divided doses from days -9 to -1 then continued 
from day +36 to 2 years after transplant. Tests for cy-
tomegalovirus (CMV) PP65 antigen or CMV DNA 
PCR were performed twice weekly. Positive cases were 
treated by preemptive therapy for at least 14-21 days or 
until antigen tests became negative.
Fluconazole was given to prevent fungal infections. 
It was started 3-6 mg/kg/day orally single dose from 
the start of conditioning regimens until +90 days after 
transplant. Empiric broad-spectrum antibiotics were 
given for febrile neutropenia. Additional supportive 
measures, such as parenteral nutrition and blood com-
ponent transfusions, were administered as necessary.
After discharge, patients were followed-up in our 
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post HCT clinic, weekly for 3 months, every two 
weeks until day +120 and thereafter as per individual 
case need. In this study, chimerism documented donor 
engraftment was confirmed by polymerase chain reac-
tion (PCR) assay of genomic DNA for short tandem 
repeats (STR) on days +15, +30 from bone marrow 
and on days +60, +90, +180, and +365 after transplant 
from peripheral blood and then it was repeated each 6 
months.
Acute GVHD (aGVHD) and chronic GVHD 
(cGVHD) were diagnosed and graded according to 
standard criteria.8,9 Neutrophil engraftment was de-
fined as a neutrophil count >0.5×109/L for at least 
3 consecutive days without growth factor support. 
Time-to-platelet engraftment was defined as the first of 
3 consecutive days on which the platelet counts were 
>20× 109/L without transfusions for 7 days. Primary 
graft failure was defined as failure to achieve a neu-
trophil count >0.5×109/L by day 42. Secondary graft 
failure was defined as initial engraftment (neutrophils 
>0.5×109/L) and subsequent decline to a neutrophil 
count <0.5×109/L.
Event-free survival (EFS) was defined as the time 
between transplantation and the earliest occurrence of 
graft failure or death from any cause. Overall survival 
(OS) was measured by the time interval between the 
date of transplantation and the date of death for any 
cause or the date of the last follow-up for survivors.
Engraftment, GVHD, and survival were the prima-
ry outcomes of interest. According to previous studies 
claiming that fludarabine was associated with improved 
engraftment and survival.7,10 We compared both group 
of patients (using or not using fludarabine). The dif-
ference between proportions was tested using the 
chi-square test. OS and EFS were evaluated using the 
Kaplan-Meier method. The log-rank test statistic was 
used to evaluate the effects of different variables such 
as conditioning regimen (fludarabine and non- fludara-
bine based conditioning regimens), year of HCT (be-
fore and after 2007), donor to recipient sex (match vs. 
mismatch), source of stem cells (PB or BM), history of 
platelet or red blood cell transfusion use before HCT 
(never vs. at least one time) and receiving corticoste-
roids before transplant with OS and EFS as outcome. 
A significance level of .05 was used for all tests. 
RESULTS
The study included 53 patients who underwent HCT 
for FA. The median age of patients and donors were 9 
(range, 2-48 years) and 23 years (range, 3-55 years), re-
spectively. Patients and donors characteristics are shown 
in Table 1. Twenty-four donors (55.8%) were female.
Thirty-six of the patients included in this study 
had received at least one prior transfusion with red 
blood cells and/or platelets. Thirty-three of 53 patients 
(62.3%) had also received treatment with corticosteroid 
prior to their transplants. Bone marrow cytology pre-
HCT was hypocellular in 51 patients and with myelo-
Table 1.  Patient, donor and transplantation characteristics. 
Non-
fludarabine Fludarabine Total
Number of patients 42 (100%) 11 (100%) 53 (100%)
Median patient age at HCT 
(range) (years)
9 (2-48) 14 (6-26) 9 (2-48)
Median donor age 
(range)(years)
22 (4-55) 23 (3-32) 23 (3-55)
Patient gender
   male 26 (62%) 5 (45.45%) 31 (58.5%)
   female 16 (38%) 6 (54.55%) 22 (41.5%)
Donor gender 
   male 19 (45%) 7 (64%) 26  (49%)
   female 23 (55%) 4 (36%) 27  (51%)
Stem cell source
   bone marrow 21 (50%) 2 (18%) 23 (43%)
   Peripheral blood 21 (50%) 9 (82%) 30 (57%)
Type of donor 
   Hla identical sibling 29 (69%) 10 (90.1%) 39 (73.6%)
   Hla match, 
   other relative 9 (21.4%) 0 (0%) 9 (17%)
   Hla mismatch, 
   sibling/other relative 4 (9.6%) 1 (9.9%) 5 (9.4%)
Status at transplantation
   Hypocellular 40 (95%) 11 (100%) 51 (96%)
   mdS 2 (5%) 0 (0%) 2 (4%)
Deformity
   Yes 35 (83.3%) 4 (36.4%) 39 (73.6%)
   no 7 (16.7%) 7 (63.6%) 14 (26.4%)
Corticosteroids before 
transplant
   Yes 24 (57%) 9 (82%) 33 (62%)
   no 18 (43%) 2 (18%) 20 (38%)
Pre-transplant transfusions 
(blood and/or platelet)
   Yes 26 (61.9%) 10 (90.9%) 36 (67.9%)
   no 16 (38.1%) 1 (9.1%) 17 (32.1%)
original research report fludarabine-baSed SCT in fanCOni anemia
Hematol Oncol Stem Cell Ther 4(3)     Third Quarter 2011 hemoncstem.edmgr.com112
dysplastic changes in 2 patients. No evidence for leuke-
mic transformation was found.
PB in 30 patients (56.6%) and BM in 23 patients 
(43.4%) were used as the source of stem cells. Twenty-six 
patients (50.4%) were sex-matched with their donors.
For graft-versus host disease (GVHD) prophylaxis, 16 
patients received ciclosporin alone and 37 patients received 
ciclosporin and methotrexate at standard doses (46.7%).
Graft failure occurred in 4 patients; 2 had primary 
graft failure, while 2 other patients experienced second-
ary graft failure. All these 4 patients (3 patients received 
an HLA-identical sibling HCT and one patient under-
went HCT from his one-antigen mismatched father) 
died following HCT. Pre-transplant details of these 
patients are described in Table 2.
Thirty-eight patients (71.7%) developed aGVHD; 
33 patients (86.8%) had involvement of their skin, 28 
patients (73.6%) had gastrointestinal involvement and 
21 patients (65.3%) had liver involvement. Eleven of 43 
patients (25.6%) who remained alive until day +100 de-
veloped cGVHD (Table 3).
The median duration of follow-up for survivors 
was 13 months. The 3-year overall survival was 60.6% 
(SE=7.3%) (Figure 1). The main cause of death was 
GVHD in 6 cases (31.6%). Causes of death among pa-
tients conditioned with regimens are described in Table 
4. The 3-year OS for patients in the non-fludarabine 
and fludarabine groups was 70% and 36.4%, respective-
ly. However, there were no statistically significant differ-
ences between these two groups  (P=.112) (Figure 2).
The occurrence of aGVHD was statistically high-
er in the non-fludarabine group. Acute GVHD after 
transplantation in the non-fludarabine and fludarabine 
groups was 78.6% and 45.5%, respectively (P=.03). 
There were no statistically significant differences in 
risks of cGVHD by conditioning regimens. Chronic 
GVHD in the non-fludarabine and fludarabine groups 
was 20.6% and 44.4%, respectively (P=.14). 
Our study identified that there was a statistically signif-
icant relationship in the 3-year OS between patients who 
underwent transplantation before and after 2007(P=.05).
Comparing survival rates between patients who did 
or did not receive platelet or red blood cell transfusion 
before HCT (never vs. at least one time) was not sta-
tistically significant (P=.31). There was no statistically 
significant difference in survival rate of patients receiv-
ing corticosteroids before transplant (P=.97). The 
study of other variables including donor to recipient sex 
(match vs. mismatch) and source of stem cells (PB or 
BM) were not significant predictors of OS and EFS in 
patients (P=.12) (P=.28).
DISCUSSION
Over the years, radiation has been used as a condition-
ing regimen in HCT for FA,11-15 but due to radiosensi-
tivity and an increased risk of developing cancer in FA 
patients,16,17 conditioning regimens without total body 
Table 2.  Pre-transplant details of the four patients with graft failure.
 1 2 3 4
age (years) 18 14 8 9
donor/recipient sex m/m m/m f/m m/f
donor relationship Sibling Sibling Sibling father
Hla typing identical identical identical mismatched
abO of donor-
patient a+/a+ O+/O+ ab+/ab+ O+/O+
no. of previous 
packed cell 
transfusion (units)
62 0 5 4
no. of previous 
platelet transfusion 
(units)
250 15 25 2
no. of nucleated 
marrow cells 
(108/kg)
5.45 6.2 7 3.25
Table 3.  acute and chronic graft-versus-host disease.
Non-fludarabine Fludarabine
Acute GVHD               33 (79%) 5 (45%)
Grading
  i 11 (33.3%) 3 (60%)
  ii 6 (15.2%) 1 (20%)
  iii 10 (30.4%) 1 (20%)
  iV 7 (21.1%) 0 (o%)
Organ impairment
  Skin 30(91%) 5(100%)
  Gi tract 26(79%) 4(80%)
  liver 20(60.61%) 4(80%)
  Chronic GVHd 7 (16.8%) 4 (36.4%)
Grading
  limited 5 (71%) 3 (75%)
  extensive 2 (29%) 1 (25%)
Severity
  mild 3(42.86%) 3(75%)
  moderate 4(57.14%) 1(25%)
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irradiation (TBI) have been used for transplantation. 
Cyclophosphamide with or without busulfan was first 
used,18-20 and then FA patients were conditioned with 
fludarabine before HCT.21-25 Bitan et al13 successfully 
transplanted matched related and unrelated HCT us-
ing a fludarabine-based reduced intensity conditioning 
regimen in FA patient.
Results of unrelated donor HCT have been less 
encouraging, mainly due to increased difficulties with 
engraftment and a higher incidence of both acute 
and chronic graft-versus-host disease (GVHD).22,26 
However, even in the HLA identical transplant setting, 
FA patients remained at increased risk of severe GVHD 
when compared to patients with severe idiopathic aplas-
tic anemia, because the defective DNA repair machin-
ery renders tissues more prone to become a target of the 
alloreactive aggression leading to GVHD.27
In this retrospective single-center study we describe 
the outcomes in 53 FA patients who underwent HCT 
using two different conditioning regimens. In our study, 
the overall 3-year OS rate was 60.2%. The 3-year OS 
rate in the non-fludarabine and fludarabine groups was 
70% and 36.4%, respectively. In 2009, Locatelli, et al 
conducted a study on 64 patients diagnosed with FA.7 
Based on the findings of this survey, the overall 8-year 
survival rate was 86% for recipients of fludarabine-
based conditioning regimens. The results of another 
study conducted by Stepansky indicated that the overall 
survival rate after a median follow-up of 32 months in 
41 HCT recipients who had received fludarabine and 
non-fludarabine-based conditioning regimens was 83% 
and 35%, respectively.28 The major factors leading to the 
differences between the results of the present and other 
previous studies seem to be related to differences in his-
tological status of patients, different types of condition-
ing regimens used in patients’ treatment and differences 
seen in mutations in different patients.
Four of 11 patients transplanted using fludara-
bine-based conditioning regimens died of graft failure 
incidence following HCT. The graft failure rate in the 
fludarabine group was reported to be 36.4% versus 0% 
in the non-fludarabine group. The current study had 
better results in graft failure when compared with the 
results of the study conducted by Torjeman et al in 
2007.29 The study surveyed 17 patients with Fanconi 
anemia who had received a regimen consisted of Bu 4 
mg/kg and cyclophosphomide 40 mg/kg before trans-
plantation. The graft failure rate was reported to be 
18% in the post-transplant period. The cause of better 
quality of engraftment in our study could be related to 
higher dose of cyclosphamide used in treatment (60 
mg/kg versus 40 mg/kg), which resulted in better im-
Figure 1. Probability of overall survival in 53 patients who 
underwent HCT.
Figure 2. Probability of overall survival after fludarabine and 
nonfludarabine regimens.
Table 4. Causes of death according to conditioning regimens.
Conditioning 
regime
No. of 
patient
No. of 
death
Cause of 
death (no. of 
patients)
flu
11 6
Primary graft 
failure (2)
Cy Secondary graft failure (2)
haTG GvHd (1)
PTld (1)
Oral bu
42 13
infection (5)
Cy GvHd (5)
haTG brain hemorrhage (1)
TTP (1)
ardS (1)
flu: fludarabine, Cy: Cyclophosphamide, haTG: Horse antithymocyte globulin, bu: 
busulfan, PTlT: Post transplant lymphoproliferative disorder, TTP: Thrombotic 
thrombocytopenic purpura ardS: adult respiratory distress syndrome
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munosuppressive impact.
The incidence of aGVHD and cGVHD in the 
fludarabine group was 78.6% and 20.6%, respec-
tively. These results are higher than those reported by 
Torjemane et al where the incidence of aGVHD and 
cGVHD was 23% and 13%, respectively.29 FA patients, 
especially younger patients with extensive malformation 
syndromes, represent a group at risk of GVHD in the 
post-transplant period.27 As the intensity of associated 
malformation syndromes was not recorded, the corre-
lation between malformation syndromes and GVHD 
development in patients with FA has not been reported 
in our study, but it could be deduced that the high rate 
of aGVHD can be associated with the different types of 
malformation syndromes and patient age.
Despite the high incidence of aGVHD in the non-
fludarabine group, which resulted in the death of some 
patients, OS and EFS were significantly better than in 
the fludarabine group. Thus, in spite of the fact that re-
cent studies advocate the fludarabine-based condition-
ing regimens,7,19,22 we propose to conduct a multicenter, 
prospective study to evaluate the outcomes of regimens 
employed in FA patients.
Further investigations on the relationship between 
the type of regimen used in transplantation and the 
type of gene mutation in Iranian patients can determine 
which treatment regimens can help patients to achieve a 
better quality of life.
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